Novo Nordisk developed semaglutide for diabetes treatment under the Ozempic brand.
Novo Nordisk is a Danish pharmaceutical company specializing in diabetes and obesity care. Its history dates to the 1920s, when separate Danish companies began producing insulin. Novo and Nordisk merged in 1989, creating the modern company. It has since become one of the world’s most valuable healthcare businesses, with demand for diabetes and obesity medicines driving major growth.
Ozempic is a once-weekly injectable medicine containing semaglutide and is approved for adults with type 2 diabetes alongside diet and exercise. Semaglutide also appears in other products: Wegovy is approved for chronic weight management in eligible patients, while Rybelsus is an oral semaglutide product for type 2 diabetes in certain markets.
A common mix-up is treating Ozempic and Wegovy as identical brands. They contain the same active ingredient but have different approved indications and dosing frameworks. Novo Nordisk’s market value reflects its pharmaceutical portfolio, manufacturing capacity, and expectations surrounding metabolic-disease treatment.